Using nanoparticles to improve HIV vaccine delivery
Lymph node targeting nanoparticles for HIV Env proteins
This study is looking at a new way to help the body create a stronger immune response to HIV by using tiny biodegradable particles to deliver important proteins to the lymph nodes, which could lead to a better HIV vaccine for everyone.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Florida State University NIH-funded |
| Lab location | 1 site (Tallahassee, United States) |
| Project ID | NIH-11014236 on NIH RePORTER |
What this research studies
This research focuses on developing biodegradable nanoparticles that can effectively deliver HIV Env proteins to lymph nodes, which is crucial for eliciting a strong immune response. By enhancing the delivery method, the study aims to improve the generation of broadly neutralizing antibodies (bNAbs) that are essential for an effective HIV vaccine. The approach involves targeting the lymphatic system to ensure better recognition and uptake of the HIV proteins, potentially leading to improved vaccine efficacy. The research is particularly significant given the ongoing need for a safe and effective HIV vaccine despite advancements in treatment.
Who could benefit from this research
Good fit: Ideal candidates for this research would be individuals at risk of HIV infection who are interested in participating in vaccine trials.
Not a fit: Patients who are already living with HIV and are on antiretroviral therapy may not directly benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to the development of a more effective HIV vaccine, reducing new infections and improving public health outcomes.
How similar studies have performed: While the approach of using nanoparticles for vaccine delivery is promising, it is still an emerging field with limited prior success specifically targeting HIV.
Where this research is happening
Tallahassee, United States
- Florida State University — Tallahassee, United States (Active)
Researchers
- Principal investigator: Mousa, Jarrod — Florida State University
- Study coordinator: Mousa, Jarrod
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.